PARP1 and neoplasm: In addition to being approved for treatment of ovarian cancer, PARP inhibitors are currently in clinical trials in a range of other tumour types with promising results (Kaufman et al., 2015; Liu et al., 2014; Mateo et al., 2015; Oza et al., 2015).